(19)
(11) EP 1 578 799 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.03.2011 Bulletin 2011/12

(45) Mention of the grant of the patent:
30.06.2010 Bulletin 2010/26

(21) Application number: 03796574.6

(22) Date of filing: 02.12.2003
(51) International Patent Classification (IPC): 
C07K 16/00(2006.01)
A61K 39/395(2006.01)
A61P 37/00(2006.01)
G01N 33/577(2006.01)
 C07K 16/24(2006.01)
A61P 35/00(2006.01)
A61P 19/02(2006.01)
G01N 33/68(2006.01)
(86) International application number:
PCT/US2003/038281
(87) International publication number:
WO 2004/050683 (17.06.2004 Gazette 2004/25)

(54)

ANTIBODIES DIRECTED TO TUMOR NECROSIS FACTOR AND USES THEREOF

GEGEN DEN TUMOR NEKROSE FAKTOR GERICHTETE ANTIKÖRPER UND DEREN VERWENDUNGEN

ANTICORPS AGISSANT SUR LE FACTEUR DE NECROSE DES TUMEURS (TNF) ET LEURS UTILISATIONS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 02.12.2002 US 430729 P

(43) Date of publication of application:
28.09.2005 Bulletin 2005/39

(73) Proprietor: Amgen Fremont Inc.
Fremont, CA 94555 (US)

(72) Inventors:
  • BABCOOK, John, S.
    Vancouver, British Columbia V6R 2R2 (CA)
  • KANG, Jaspal, S.
    Surrey, British Columbia V4N 5H6 (CA)
  • FOORD, Orit
    Foster City, CA 94404 (US)
  • GREEN, Larry
    San Francisco, CA 94144 (US)
  • FENG, Xiao
    Union City, CA 94587 (US)
  • KLAKAMP, Scott
    Fremont, C A 94538 (US)
  • HAAK-FRENDSCHO, Mary
    Newark, CA 94560 (US)
  • RATHANASWAMI, Palaniswami
    Vancouver, British Columbia V6P 4V7 (CA)
  • PIGOTT, Craig
    Vancouver, British Columbia V6E 1M1 (CA)
  • LIANG, Meina, L.
    Danville, CA 94526 (US)
  • LEE, Rozanne
    Newark, CA 94560 (US)
  • MANCHULENCHO, Kathy
    Port Coquitlam, B.C. V3C6P9 (CA)
  • FAGGIONI, Raffaella
    Pleasanton, CA 94566 (US)
  • SENALDI, Giorgio
    Dublin, CA 94568 (US)
  • SU, Qiaojuan Jane
    San Jose, CA 95135 (US)

(74) Representative: Paemen, Liesbet R.J. et al
De Clercq & Partners cvba Edgard Gevaertdreef 10 a
9830 Sint-Martens-Latem
9830 Sint-Martens-Latem (BE)


(56) References cited: : 
EP-A- 0 614 984
US-B1- 6 258 562
 US-A- 6 090 382
   
  • KEMPENI J: "Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7" ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 58, no. 3, 1999, pages I70-I72, XP002979958 ISSN: 0003-4967
  • KEMPENI J: "UPDATE ON D2E7: A FULLY HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY" ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 59, no. SUPPL 1, November 2000 (2000-11), pages I44-I45, XP008061368 ISSN: 0003-4967
  • TAYLOR P C: "ANTI-TUMOR NECROSIS FACTOR THERAPIES" CURRENT OPINION IN RHEUMATOLOGY, CURRENT SCIENCE, LONDON, GB, vol. 13, no. 3, 2001, pages 164-169, XP009059894 ISSN: 1040-8711
  • FELDMANN M: "DEVELOPMENT OF ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS" NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 2, May 2002 (2002-05), pages 364-371, XP008065663 ISSN: 1474-1733
  • GLENNIE M J ET AL: "Clinical trials of antibody therapy" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 403-410, XP004215169 ISSN: 0167-5699
  • BASELGA J ET AL: "PHASE I STUDIES OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR CHIMERIC ANTIBODY C225 ALONE AND IN COMBINATION WITH CISPLATIN" JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 18, no. 4, February 2000 (2000-02), pages 904-914, XP009053775 ISSN: 0732-183X
  • MUKHTYAR C ET AL: "CURRENT" JOURNAL OF FORENSIC SCIENCES, CALLAGHAN AND CO., CHICAGO, IL,, US, vol. 64, no. SUPPL 4, November 2005 (2005-11), pages 31-36, XP008065805 ISSN: 0022-1198
  • HOCHBERG M C ET AL: 'Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when adda to methotrexate in patients with active rheumatoid arthritis' ANN RHEUM DIS vol. 62, no. 2-SUPP, 2003, pages II13 - II16, XP002985919
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).